AlvotechALVO stock score: 55/100
$4.29 · -5.71% · Scored Nov 19, 2026
- Technical
- 34
- Fundamental
- 61
- News
- 52
The reading
Alvotech (ALVO) scores 55 out of 100, which reads neutral, higher than 62% of Healthcare stocks and 61% of the 4,118 US stocks we score.
The composite weights fundamentals 80% and technicals 20%: fundamentals read 61, technicals 34.
Among the fundamentals, Price Target at 100 and Revenue Growth (Annual) at 100 score highest, while Earnings Growth (Quarterly) at 0 weighs the most against it.
On the daily chart, trend-following indicators average 29 and contrarian oscillators 63 — a split worth reading before trusting the technical total.
News sentiment is neutral at 52; it is shown, not counted in the composite.
Since Aug 24, 2026 the composite has ranged from 42 to 56, and it is up 6 points over the period.
About Alvotech
Alvotech (ALVO) is a biotechnology company based in Reykjavik, Iceland, that develops and manufactures biosimilars, which are lower-cost versions of biologic medicines whose patents have expired. Its approved products include biosimilars to Humira and Stelara, along with other biosimilars approved in various markets, and it has a pipeline of dozens more in development across several therapeutic areas. Alvotech handles development and manufacturing itself, including at its main plant in Reykjavik, and has added research capacity in Sweden by acquiring Xbrane Biopharma’s development operations, along with packaging capacity. It relies on commercial partners to sell its products in different regions, including Teva in the United States and partners such as STADA, Sandoz, Advanz Pharma and Dr. Reddy’s in other markets. Alvotech earns money from product sales to these partners and from license and milestone payments.
Alvotech competes with Sandoz, Amgen, Samsung Bioepis, Celltrion, Biocon Biologics and other biosimilar makers, as well as with the original branded drugs. Its edge rests on a dedicated biosimilar platform that covers development through manufacturing and a large pipeline backed by a network of commercial partners. Investors who follow ALVO stock tend to watch regulatory approvals and launches of new biosimilars, particularly in the United States and Europe. Inspection outcomes at its manufacturing facilities are closely followed. Product revenue growth, partner sales performance, margins, debt and cash flow are other factors.
What’s driving the score
The strongest and weakest of the scorers that count toward ALVO’s composite. Each returns 0–100, higher is more bullish — including metrics where low is good, like P/E.
Fundamental
61Pulling it up
- Price Target100
Price target score compares the current stock price to analyst consensus targets.
Annual revenue growth tracks year-over-year sales expansion.
Net income growth from the prior fiscal year to the latest.
Holding it back
Net income growth against the same quarter a year earlier, weighted toward the latest quarter.
Profit margins show what percentage of revenue becomes profit.
Free cash flow yield is free cash flow divided by market value: the cash a business generates for each dollar of its price.
34 weighted scorers; 5 had no data today and are left out rather than counted as zero.
Technical · daily
33Pulling it up
Bollinger Bands (20-period) plot standard deviations above and below a moving average.
Bollinger Bands (50-period) measure where price sits between bands two standard deviations around its 50-period average.
Where the close sits against its 200-day SMA.
Holding it back
Candlestick patterns recognize specific price formations that historically suggest continuation or reversal.
Ichimoku Cloud is a comprehensive indicator showing support/resistance, trend direction, and momentum.
- VWAP0
Volume Weighted Average Price (VWAP) shows the average price weighted by volume.
62 weighted scorers; 3 had no data today and are left out rather than counted as zero.
News · shown, not counted
- Global News
- 52
Technical score by timeframe
| Chart | Score | Weight |
|---|---|---|
| Hourly | 36 | 1 |
| Daily | 33 | 3 |
| Weekly | 31 | 2 |
| Monthly | 36 | 2 |
Composite score, last 90 days
Show the daily numbers
| Date | Composite |
|---|---|
| Nov 20, 2026 | 55 |
| Nov 19, 2026 | 56 |
| Nov 18, 2026 | 55 |
| Nov 16, 2026 | 55 |
| Nov 14, 2026 | 54 |
| Nov 13, 2026 | 56 |
| Nov 12, 2026 | 46 |
| Nov 11, 2026 | 46 |
| Nov 8, 2026 | 46 |
| Nov 7, 2026 | 45 |
| Nov 6, 2026 | 43 |
| Nov 5, 2026 | 45 |
| Nov 4, 2026 | 44 |
| Nov 3, 2026 | 43 |
| Nov 2, 2026 | 44 |
| Oct 31, 2026 | 43 |
| Oct 30, 2026 | 45 |
| Oct 29, 2026 | 45 |
| Oct 28, 2026 | 43 |
| Oct 27, 2026 | 42 |
| Oct 26, 2026 | 42 |
| Oct 25, 2026 | 42 |
| Oct 24, 2026 | 42 |
| Oct 23, 2026 | 43 |
| Oct 22, 2026 | 45 |
| Oct 21, 2026 | 45 |
| Oct 20, 2026 | 44 |
| Oct 19, 2026 | 44 |
| Oct 18, 2026 | 44 |
| Oct 17, 2026 | 44 |
| Oct 16, 2026 | 46 |
| Oct 15, 2026 | 46 |
| Oct 14, 2026 | 46 |
| Oct 13, 2026 | 47 |
| Oct 12, 2026 | 47 |
| Oct 11, 2026 | 47 |
| Oct 10, 2026 | 48 |
| Oct 9, 2026 | 47 |
| Oct 8, 2026 | 49 |
| Oct 7, 2026 | 51 |
| Oct 6, 2026 | 50 |
| Oct 5, 2026 | 47 |
| Oct 4, 2026 | 47 |
| Oct 3, 2026 | 47 |
| Oct 2, 2026 | 47 |
| Oct 1, 2026 | 48 |
| Sep 30, 2026 | 49 |
| Sep 29, 2026 | 50 |
| Sep 28, 2026 | 48 |
| Sep 27, 2026 | 48 |
| Sep 26, 2026 | 48 |
| Sep 25, 2026 | 49 |
| Sep 24, 2026 | 50 |
| Sep 23, 2026 | 49 |
| Sep 22, 2026 | 49 |
| Sep 21, 2026 | 50 |
| Sep 20, 2026 | 50 |
| Sep 19, 2026 | 50 |
| Sep 18, 2026 | 49 |
| Sep 17, 2026 | 48 |
| Sep 16, 2026 | 46 |
| Sep 15, 2026 | 47 |
| Sep 14, 2026 | 49 |
| Sep 13, 2026 | 49 |
| Sep 12, 2026 | 48 |
| Sep 11, 2026 | 48 |
| Sep 10, 2026 | 48 |
| Sep 9, 2026 | 48 |
| Sep 8, 2026 | 48 |
| Sep 7, 2026 | 49 |
| Sep 6, 2026 | 48 |
| Sep 5, 2026 | 49 |
| Sep 4, 2026 | 50 |
| Sep 3, 2026 | 49 |
| Sep 2, 2026 | 49 |
| Sep 1, 2026 | 50 |
| Aug 31, 2026 | 49 |
| Aug 30, 2026 | 49 |
| Aug 29, 2026 | 49 |
| Aug 28, 2026 | 48 |
| Aug 27, 2026 | 49 |
| Aug 26, 2026 | 49 |
| Aug 25, 2026 | 50 |
| Aug 24, 2026 | 49 |
Key facts
- Market cap
- $1.5B
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Beta
- 0.24
- Risk grade (1–10)
- —
- Next earnings
- Nov 11, 2026
Specialty & Generic Drug Manufacturers peers
| Company | Market cap | Score |
|---|---|---|
| BCRX BioCryst Pharmaceuticals | $1.9B | 72 |
| ETON Eton Pharmaceuticals | $1.8B | 63 |
| ANIP ANI Pharmaceuticals | $1.6B | 67 |
| PCRX Pacira BioSciences | $1.5B | 65 |
| PAHC Phibro Animal Health | $1.4B | 63 |
| HROW Harrow | $1.2B | 57 |
All Specialty & Generic Drug Manufacturers stocks, highest-scored first
Questions
What is ALVO's stock rating today?
ALVO scores 55/100 (Neutral) as of Nov 19, 2026: technical 34, fundamental 61, and news sentiment 52, which is shown but not counted. Scores are recomputed every night.
What does Alvotech do?
Alvotech (ALVO) is a biotechnology company based in Reykjavik, Iceland, that develops and manufactures biosimilars, which are lower-cost versions of biologic medicines whose patents have expired. Its approved products include biosimilars to Humira and Stelara, along with other biosimilars approved in various markets, and it has a pipeline of dozens more in development across several therapeutic areas.
Is ALVO stock a buy?
The score is not a buy or sell recommendation. A 55 says the technical and fundamental signals we measure lean neutral today, relative to every other stock scored the same way. Use the breakdown above to see why, and treat it as a starting point for your own research.
How is the ALVO score calculated?
96 weighted scorers feed it today: 34 fundamental, scored against Healthcare ranges, and 62 technical on the daily chart, with 4 timeframes blended into the technical total. Every scorer returns 0–100; missing data is left out, never counted as zero.
Scores are information, not investment advice. Computed from Yahoo Finance, Finnhub and Alpha Vantage data; technical indicators via TA-Lib. Past scores do not predict future returns.
Embed this score
A badge for a blog post, newsletter or README. It updates every night and links back here. More badges
HTML
<a href="https://stocksscores.com/stocks/alvo/"><img src="https://stocksscores.com/stocks/alvo/badge.svg" alt="ALVO stock score" height="20"></a>
Markdown
[](https://stocksscores.com/stocks/alvo/)